A next generation diagnostic device that effectively screens for breast cancer in all tissue types, without the use of ionising radiation

Informazioni relative al progetto

OE Scan

ID dell’accordo di sovvenzione: 807804

DOI

10.3030/807804

Progetto chiuso

Data della firma CE 23 Febbraio 2018

Data di avvio 1 Gennaio 2018

Data di completamento 30 Aprile 2018

Finanziato da

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

TIRO MEDICAL LTD
United Kingdom

Periodic Reporting for period 1 - OE Scan (A next generation diagnostic device that effectively screens for breast cancer in all tissue types, without the use of ionising radiation)

Periodo di rendicontazione: 2018-01-01 al 2018-04-30

Sintesi del contesto e degli obiettivi generali del progetto

Our Breast screening technology is intended to increase breast cancer detection in the female population. Our imaging device will greatly improve the accuracy of breast cancer screening. The current gold standard technique, mammography, fails to detect around half of cancers in women with dense breast tissue. These cancers will eventually be diagnosed, but will likely have progressed to a stage requiring more expensive treatments. Our product is a simple and highly effective screening device which is aimed to be the leading personalised screening tool for woman underserved by mammography. Our technology will increase the accurate detection of breast cancer, enabling clinicians to carry out earlier interventions and make better informed decisions. In addition it will improve screening programme compliance due to lack of radiation and pain.

We now need to update the device with engineering upgrades, gain medical device certification, and perform and pivotal clinical trial.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

During the study we redefined the product specification based on the user requirements. From this updated specification we built up a development plan to achieve the defined specification and the cost to achieve this. We assessed the development plan and took into consideration what activities could be undertaken in house and where we would need to include external support. We identified the need for a Contract Manufacturing Organisation for the device manufacturing, a Clinical Research Organisation for managing the pivotal trial, and Breast Centres for providing study participants. We then initiated contact with these organisation.
We also undertook a deeper market analysis in which we identified 5 market segments and we defined each of their market size. We also undertook a deeper analysis of market risks and a barriers. Financial projections were also updated based on the updated market data and costs of development.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

X-ray mammography is currently the preferred technology of choice with over 18 million women undergoing mammography each year. The main competitors in this space are GE Healthcare, Siemens. Toshiba Medical Systems Corp. and Hologic Inc. Our device will act as an additional personalised test for women that are underserved by current screening systems in order to improve clinical decision-making.

tiro-medical.jpg